The Phase 3 data are highly compelling across all endpoints with a clean safety profile, de-risking the BLA submission. The stock should re-rate on the probability of approval and commercial launch in H1 2027. Monitor FDA acceptance of the rolling BLA and any AdCom scheduling.
Price Chart
Executive Summary
Intellia presented additional positive Phase 3 HAELO data for lonvo-z (NTLA-2002) in HAE at EAACI 2026, with the manuscript simultaneously published in NEJM. All key secondary endpoints were met with high statistical significance, including an 89% reduction in attacks requiring on-demand treatment and a 91% reduction in moderate/severe attacks. A rolling BLA submission was initiated in April, with regulatory approval and U.S. launch anticipated in H1 2027.
Key Facts
- Phase 3 HAELO trial met primary endpoint with 87% reduction in mean monthly attacks (p<0.0001) for lonvo-z vs placebo.
- 62% of lonvo-z patients were attack-free and therapy-free for the six-month efficacy evaluation period vs 11% placebo (p<0.0001).
- Key secondary endpoints: 89% reduction in attacks requiring on-demand treatment, 91% reduction in moderate/severe attacks, and -17.04 improvement in AE-QoL (all p<0.0001).
- No serious adverse events in the lonvo-z arm; all TEAEs were mild or moderate.
- Rolling BLA submission initiated with FDA in April 2026; regulatory approval and U.S. launch expected in H1 2027.
- Lonvo-z has Orphan Drug, RMAT, Innovation Passport, PRIME, and EU Orphan Drug designations.
Financial Impact
First-in-class in vivo CRISPR gene therapy for HAE with potential to transform treatment paradigm; peak sales could exceed $1B given HAE prevalence (1 in 50,000) and one-time curative profile. No financial figures provided in release.
Risk Factors
- FDA could issue a CRL on CMC or manufacturing grounds despite strong efficacy data.
- Commercial adoption may be slower than expected if payers impose restrictions on one-time gene therapy pricing.
- Competition from existing prophylactic therapies (Takhzyro, Haegarda, Orladeyo) with established market presence.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 1 press release from GlobeNewswire.
| Document | Accession Number |
|---|---|
| PRESS-RELEASE Data (Synthetic) | press-3311378 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Oct 2, 2026 24d ago | Press Release | $12.75 $12.58 | ▼ −1.33% | ▼ −1.76% | $11.26 (−11.69%) |
Sep 8, 2026 6w ago | 8-K | $12.21 $11.60 | ▼ −5.00% | ▼ −4.66% | $11.26 (−7.78%) |
Aug 6, 2026 11w ago | 8-K | $11.24 $11.83 | ▲ +5.25% | ▲ +4.04% | $11.26 (+0.18%) |
Jun 15, 2026 19w ago | 8-K | $14.92 $15.75 | ▲ +5.56% | ▲ +6.95% | $11.26 (−24.53%) |
Jun 13, 2026 19w ago | Press Release | $14.92 $15.75 | ▲ +5.56% | ▲ +6.95% | $11.26 (−24.53%) |
Jun 1, 2026 21w ago | Press Release | $13.73 $13.54 | ▼ −1.38% | ▲ +1.37% | $11.26 (−17.99%) |
May 11, 2026 24w ago | 8-K | $14.42 $12.69 | ▼ −12.00% | ▼ −11.91% | $11.26 (−21.91%) |
Apr 27, 2026 26w ago | Press Release | $13.20 $13.87 | ▼ −5.08% | ▼ −3.38% | $11.26 (+14.70%) |
Apr 27, 2026 26w ago | 8-K | $13.04 $13.87 | ▲ +6.37% | ▲ +5.96% | $11.26 (−13.65%) |
Apr 3, 2026 29w ago | Press Release | $13.30 $14.26 | ▲ +7.22% | ▲ +3.08% | $11.26 (−15.34%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers